EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gut Microbiota in NAFLD/MASLD: Functional Dysbiosis and the Gut–Liver Axis in Disease Progression

Marica Colella, Rossana Notaristefano, Maria Tragni, Manuela Mandorino

Livers · 04.09.2026 · 6 (5) · 93

DOI: 10.3390/livers6050093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Livers, online erschienen am 04.09.2026. Verfasst von Marica Colella und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non-alcoholic fatty liver disease (NAFLD), now largely encompassed by the metabolic dysfunction-associated steatotic liver disease (MASLD) framework, is a leading cause of chronic liver disease worldwide and is closely linked to obesity, insulin resistance, type 2 diabetes (T2D), and cardiometabolic dysfunction. Although hepatic lipid accumulation and metabolic injury remain central to its pathogenesis, increasing evidence implicates the intestinal microbiota as a modulator of disease onset and progression through the gut–liver axis.

Objectives

This narrative review summarizes current evidence linking gut microbiota to NAFLD/MASLD, with emphasis on functional microbial alterations relevant to the gut–liver axis, disease severity, microbiota-related biomarkers, and microbiota-targeted interventions.

Methods

The literature search for this narrative review was mainly performed using PubMed/MEDLINE (which produced 200 results since 2023). The search addressed the relationship between gut microbiota, NAFLD/MASLD, and gut–liver axis dysfunction.

Results

Early studies mainly focused on disease-associated bacterial taxa; however, no consistent microbial signature has been reproduced across populations, disease stages, and methodological platforms. This limitation supports a shift from a taxonomic view of dysbiosis toward a functional interpretation. Different microbial communities may converge on shared pathogenic outputs, including impaired epithelial barrier integrity, microbial translocation, lipopolysaccharide-driven Toll-like receptor 4 activation, bile acid remodelling, altered short-chain fatty acid production, endogenous ethanol generation, choline and trimethylamine-N-oxide metabolism, and tryptophan-derived indole signalling. These mechanisms may influence hepatic steatosis, inflammatory activation, and fibrogenesis.

Conclusions

Current data support the microbiota as a biologically plausible disease modifier, but not yet as a standalone diagnostic or therapeutic target; clinical translation will require longitudinal, multi-omics, and function-oriented studies.

Zitieren

APA

Colella, M., Notaristefano, R., Tragni, M., & Mandorino, M. (2026). Gut Microbiota in NAFLD/MASLD: Functional Dysbiosis and the Gut–Liver Axis in Disease Progression. Livers, 6(5), 93. https://doi.org/10.3390/livers6050093

Vancouver

Colella M, Notaristefano R, Tragni M, Mandorino M. Gut Microbiota in NAFLD/MASLD: Functional Dysbiosis and the Gut–Liver Axis in Disease Progression. Livers. 2026;6(5):93. doi:10.3390/livers6050093

BibTeX
@article{Colella2026,
  author = {Colella, Marica and Notaristefano, Rossana and Tragni, Maria and Mandorino, Manuela},
  title = {Gut Microbiota in NAFLD/MASLD: Functional Dysbiosis and the Gut–Liver Axis in Disease Progression},
  journal = {Livers},
  year = {2026},
  volume = {6},
  number = {5},
  pages = {93},
  doi = {10.3390/livers6050093}
}
Kostenlos starten →